Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching

From the scarce data available, the consequences of switching between reference product mAbs and their biosimilar(s) in the oncology setting are as yet unknown. Additional clinical evidence from well-designed switching studies is needed to guide switching decisions.